Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 16 · below the Ichimoku cloud · RSI 40 · MACD above its signal
No member of Congress has disclosed a FENC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Hackman Jeffrey SChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 1.2K | — |
| Sep 29, 2026 | Evans Terry LOfficer | Stock Award(Grant) at price 0.00 per share. | 168 | — |
| Sep 29, 2026 | Sayad Pierre Sargis Ph.D.Officer | Stock Award(Grant) at price 0.00 per share. | 168 | — |
| Sep 14, 2026 | Brughera Marco MariaDirector | Sale at price 10.29 per share. | 15.5K | $159.96K |
| Sep 14, 2026 | Brughera Marco MariaDirector | Conversion of Exercise of derivative security at price 2.11 per share. | 15.5K | $32.80K |
| Aug 31, 2026 | Raykov Rostislav ChristovFormer | Sale at price 12.11 per share. | 10K | $121.10K |
| Aug 30, 2026 | Raykov Rostislav ChristovFormer | Stock Award(Grant) at price 0.00 per share. | 2.8K | — |
| Aug 30, 2026 | Andrade Robert CChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 1.7K | — |
| Aug 30, 2026 | Hackman Jeffrey SChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 1.2K | — |
| Aug 30, 2026 | Cioffi Christiana MarieOfficer | Stock Award(Grant) at price 0.00 per share. | 156 | — |
| Aug 30, 2026 | Evans Terry LOfficer | Stock Award(Grant) at price 0.00 per share. | 168 | — |
| Aug 30, 2026 | Sayad Pierre Sargis Ph.D.Officer | Stock Award(Grant) at price 0.00 per share. | 168 | — |
| Aug 30, 2026 | Sayad Pierre Sargis Ph.D.Officer | Sale at price 12.18 per share. | 12K | $146.16K |
| Aug 27, 2026 | Andrade Robert CChief Financial Officer | Conversion of Exercise of derivative security at price 5.10 per share. | 21.9K | $111.83K |
| Aug 26, 2026 | Andrade Robert CChief Financial Officer | Sale at price 11.78 per share. | 75K | $883.50K |
| Aug 2, 2026 | Raykov Rostislav ChristovFormer | Sale at price 9.58 per share. | 10K | $95.80K |
| Jul 30, 2026 | Raykov Rostislav ChristovFormer | Stock Award(Grant) at price 0.00 per share. | 2.8K | — |
| Jul 30, 2026 | Andrade Robert CChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 1.7K | — |
| Jul 30, 2026 | Hackman Jeffrey SChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 1.2K | — |
| Jul 30, 2026 | Cioffi Christiana MarieOfficer | Stock Award(Grant) at price 0.00 per share. | 156 | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.4 | 11.9 | -27.6 | 5.5 | 53.0 | 8.3 | -11.0 | 29.0 | -13.8 | -4.4 | +32.2% | ||
| 2025 | 2.8 | 8.0 | -13.2 | -0.8 | 34.4 | 2.2 | -1.4 | 8.4 | 5.5 | -12.4 | -0.1 | -6.0 | +21.8% |
| 2024 | -11.0 | -5.2 | 17.4 | -17.4 | -26.1 | -9.9 | 5.9 | -13.9 | -10.2 | -12.8 | 39.0 | 4.3 | −43.7% |
| 2023 | 4.3 | -10.1 | -7.6 | -1.6 | -7.4 | 16.5 | 0.9 | -8.4 | -8.0 | -8.4 | 25.0 | 30.5 | +16.9% |
| 2022 | 5.7 | 20.2 | 0.2 | 3.1 | -1.1 | -2.3 | 19.7 | 4.8 | 15.7 | 8.6 | 10.9 | -1.6 | +118.2% |
| 2021 | -3.4 | 1.7 | -15.2 | 0.6 | 17.9 | -1.1 | -10.7 | 21.7 | 18.9 | -1.7 | -52.6 | 0.2 | −40.9% |
| 2020 | 2.6 | 2.9 | -13.3 | 5.2 | 18.4 | 12.8 | 1.1 | -35.1 | 10.6 | 24.8 | 3.4 | -4.7 | +14.8% |
| 2019 | 4.9 | -0.6 | -27.1 | -8.2 | -15.7 | 6.7 | 17.0 | -8.1 | 11.9 | 11.0 | 17.2 | 3.7 | +1.7% |
| 2018 | -11.7 | 4.3 | 31.0 | 3.3 | -7.7 | -9.5 | -11.9 | 3.5 | -13.9 | -11.2 | -8.0 | -4.8 | −36.3% |
| 2017 | -14.4 | 2.1 | 3.4 | −9.6% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.4M | 0.00% | 134.20K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Buy / hold / sell counts